CHARLOTTESVILLE, Va., May 7, 2026
RIVANNA announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Accuro® XV Diagnostic Ultrasound System, a next-generation AI-enabled musculoskeletal imaging platform designed to improve fracture assessment and emergency triage workflows. The regulatory clearance marks a major milestone for the medical technology company and strengthens its position in the rapidly expanding point-of-care imaging and artificial intelligence healthcare market.
The newly cleared platform enables qualified healthcare professionals to perform musculoskeletal imaging in hospitals and clinical environments using a portable volumetric ultrasound system enhanced by artificial intelligence technologies. RIVANNA stated that the clearance supports broader commercialization efforts while accelerating development of advanced AI-powered fracture detection capabilities designed to improve emergency medicine efficiency and reduce dependence on traditional radiographic imaging.
AI-Driven Ultrasound Technology Targets Fracture Care
The Accuro XV platform incorporates a conformable three-dimensional volumetric ultrasound probe capable of automating large field-of-view image acquisition after initial patient positioning. The system uses motorized linear translation technology to capture high-quality B-mode ultrasound images across a 10-centimeter scan range while adapting to irregular anatomical surfaces using a specialized polyurethane contact interface.
RIVANNA emphasized that the platform is specifically engineered for point-of-care fracture evaluation and triage decision-making without exposing patients to ionizing radiation commonly associated with conventional X-ray imaging. The company believes the technology could significantly streamline emergency department workflows, particularly in high-volume care environments where imaging resources are often limited.
Advertisement
The company is also advancing two major AI-powered modules integrated into the Accuro XV ecosystem. The first, BoneEnhance®, is an image segmentation technology designed to improve visualization of skeletal structures using machine learning. The second, known as CADe/x, is described as the first computer-aided fracture detection algorithm developed specifically for volumetric ultrasound imaging.
Both technologies are currently undergoing validation through a nationwide multi-site clinical study involving eight academic medical centers. The AI-assisted platform is expected to improve fracture detection accuracy, enhance clinician confidence, and support faster treatment decisions in urgent care and emergency settings.
Clinical Study Demonstrates Strong Diagnostic Performance
RIVANNA highlighted recent feasibility study data published in the Journal of Emergency Medicine demonstrating the system’s potential to expand musculoskeletal imaging access beyond specialist physicians. The study involved 205 patients across UVA Health and UT Southwestern Medical Center and evaluated whether non-physician operators could successfully acquire diagnostic-quality ultrasound images following minimal training.
According to the results, more than 90% of scans obtained by both non-physician operators and board-certified emergency physicians were considered adequate for diagnostic interpretation. Researchers found that non-physician users achieved clinically acceptable image quality after only one hour of hands-on training, suggesting the platform could help democratize access to advanced musculoskeletal imaging in a variety of healthcare environments.
Company executives stated that combining automated image acquisition with AI-enabled fracture detection could reduce pressure on overburdened imaging departments while supporting more efficient patient triage and emergency preparedness initiatives. The system’s integrated touchscreen interface, portable battery-powered design, and DICOM-compatible workflow architecture further support use in mobile and decentralized clinical settings.
FDA Clearance Expands MedTech Innovation Momentum
The FDA 510(k) clearance further positions RIVANNA as an emerging innovator in AI-powered medical imaging and clinical decision-support technologies. The company currently holds more than 100 patents and operates an FDA-registered, ISO 13485-certified manufacturing facility focused on developing advanced healthcare imaging solutions.
The project has also received federal support through the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Health and Human Services, reflecting broader government interest in scalable point-of-care diagnostic technologies for emergency medicine applications.
Industry analysts believe AI-enabled ultrasound systems could become increasingly important in future healthcare delivery models as hospitals seek faster, portable, and lower-cost diagnostic alternatives capable of improving patient outcomes while reducing imaging bottlenecks.
Source: RIVANNA® press release
